Lung cancer stem cell: new insights on experimental models and preclinical data.
Lung cancer stem cell: new insights on experimental models and preclinical data.
复制标题
DOI：
10.1155/2011/549181
复制
发表时间：
2011
影响因子：
--
通讯作者：
Deutsch E
中科院分区：
文献类型：
--
作者：
Rivera C;Rivera S;Loriot Y;Vozenin MC;Deutsch E
肺癌仍然是癌症死亡的主要原因。了解肺肿瘤的病理生理学应该提供机会，以防止肿瘤的发展或/和改善其治疗管理。癌症干细胞（CSC）理论是指癌细胞的亚群，也称为肿瘤起始细胞，可以驱动癌症的发展。呈现这些特征的细胞已经从肺癌中鉴定和分离。探索肺CSC特异性的细胞标志物和信号通路可能会导致治疗进展并改善肺癌患者的预后。在开发体外和体内模型方面的持续努力可能会产生可靠的工具，以更好地了解CSC的能力和测试新的治疗靶点。关于假定的CSC靶点的临床前数据现在正在出现。这些初步研究对下一代肺癌治疗至关重要。
Lung cancer remains the leading cause of cancer death. Understanding lung tumors physiopathology should provide opportunity to prevent tumor development or/and improve their therapeutic management. Cancer stem cell (CSC) theory refers to a subpopulation of cancer cells, also named tumor-initiating cells, that can drive cancer development. Cells presenting these characteristics have been identified and isolated from lung cancer. Exploring cell markers and signaling pathways specific to lung CSCs may lead to progress in therapy and improve the prognosis of patients with lung cancer. Continuous efforts in developing in vitro and in vivo models may yield reliable tools to better understand CSC abilities and to test new therapeutic targets. Preclinical data on putative CSC targets are emerging by now. These preliminary studies are critical for the next generation of lung cancer therapies.